COVID-19-associated multisystem inflammatory syndrome differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 16: | Line 16: | ||
! align="center" style="background: #4479BA; color: #FFFFFF |Kawasaki Disease Shock (KDS) | ! align="center" style="background: #4479BA; color: #FFFFFF |Kawasaki Disease Shock (KDS) | ||
! align="center" style="background: #4479BA; color: #FFFFFF |Toxic Shock Syndrome (TSS) | ! align="center" style="background: #4479BA; color: #FFFFFF |Toxic Shock Syndrome (TSS) | ||
! align="center" style="background: #4479BA; color: #FFFFFF |Viral Pneumonia<ref name="pmid21435708">{{cite journal| author=Ruuskanen O, Lahti E, Jennings LC, Murdoch DR| title=Viral pneumonia. | journal=Lancet | year= 2011 | volume= 377 | issue= 9773 | pages= 1264-75 | pmid=21435708 | doi=10.1016/S0140-6736(10)61459-6 | pmc=7138033 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21435708 }}</ref> | |||
|- | |- | ||
|'''Age (median, IQR)''' | |'''Age (median, IQR)''' | ||
| Line 22: | Line 23: | ||
|3.8 (0.2-18) | |3.8 (0.2-18) | ||
|7.38 (2.4-15.4) | |7.38 (2.4-15.4) | ||
|< 5 years | |||
|- | |- | ||
|'''Total [[white blood cell]] count (*10^9/L)''' | |'''Total [[white blood cell]] count (*10^9/L)''' | ||
| Line 28: | Line 30: | ||
|12.1 (7.9-15.5) | |12.1 (7.9-15.5) | ||
|15.6 (7.5-20) | |15.6 (7.5-20) | ||
|10.0 | |||
|- | |- | ||
|'''[[Neutrophil]] count (*10^9/L)''' | |'''[[Neutrophil]] count (*10^9/L)''' | ||
| Line 34: | Line 37: | ||
|5.5 (3.2-10.3) | |5.5 (3.2-10.3) | ||
|16.4 (12-22) | |16.4 (12-22) | ||
|3.2 (1.0-5.1) | |||
|- | |- | ||
|'''[[Lymphocyte]] count (*10^9/L)''' | |'''[[Lymphocyte]] count (*10^9/L)''' | ||
| Line 40: | Line 44: | ||
|1.6 (1-2.5) | |1.6 (1-2.5) | ||
|0.63 (0.41, 1.13) | |0.63 (0.41, 1.13) | ||
|4.5 (2.7-6.1) | |||
|- | |- | ||
|'''[[Hemoglobin]] (g/L)''' | |'''[[Hemoglobin]] (g/L)''' | ||
| Line 46: | Line 51: | ||
|107 (98-115) | |107 (98-115) | ||
|114 (98-130) | |114 (98-130) | ||
| - | |||
|- | |- | ||
|'''[[Platelet]] number (10^9/L)''' | |'''[[Platelet]] number (10^9/L)''' | ||
| Line 52: | Line 58: | ||
|235 (138-352) | |235 (138-352) | ||
|155 (92- 255) | |155 (92- 255) | ||
|387 (+/-174) | |||
|- | |- | ||
|'''[[C-reactive protein]] (mg/L)''' | |'''[[C-reactive protein]] (mg/L)''' | ||
| Line 58: | Line 65: | ||
|193 (83-237) | |193 (83-237) | ||
|201 (122, 317) | |201 (122, 317) | ||
|3.4 (0.2-29) | |||
|- | |- | ||
|'''[[ALT]] (IU/L)''' | |'''[[ALT]] (IU/L)''' | ||
| Line 64: | Line 72: | ||
|73 (34-107) | |73 (34-107) | ||
|30.00 (22.10, 49.25) | |30.00 (22.10, 49.25) | ||
| - | |||
|- | |- | ||
|'''[[Albumin]] (g/L)''' | |'''[[Albumin]] (g/L)''' | ||
| Line 70: | Line 79: | ||
|30 (27-35) | |30 (27-35) | ||
|27.00 (21.00, 31.00) | |27.00 (21.00, 31.00) | ||
| - | |||
|- | |- | ||
|'''[[Ferritin]] (ug/L)''' | |'''[[Ferritin]] (ug/L)''' | ||
| Line 75: | Line 85: | ||
|200 (143-243) | |200 (143-243) | ||
|301 (228-337) | |301 (228-337) | ||
| - | |||
| - | | - | ||
|- | |- | ||
| Line 81: | Line 92: | ||
|41 (12-102) | |41 (12-102) | ||
|396 (57-1520) | |396 (57-1520) | ||
| - | |||
| - | | - | ||
|- | |- | ||
| Line 87: | Line 99: | ||
|10.0 (10-20) | |10.0 (10-20) | ||
|10 (10-30) | |10 (10-30) | ||
| - | |||
| - | | - | ||
|- | |- | ||
| Line 93: | Line 106: | ||
|1650 (970-2660) | |1650 (970-2660) | ||
|2580 (1460- 2990) | |2580 (1460- 2990) | ||
| - | |||
| - | | - | ||
|} | |} | ||
*To view the differential diagnosis of COVID-19, [[COVID-19 differential diagnosis|click here]].<br /> | *To view the differential diagnosis of COVID-19, [[COVID-19 differential diagnosis|click here]].<br /> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 01:33, 21 July 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: José Eduardo Riceto Loyola Junior, M.D.[2]
Overview
COVID-19-associated multisystem inflammatory syndrome must be differentiated from other diseases that cause conjunctival injection, cervical lymphadenopathy, and erythematous hands and feet, such as Kawasaki's disease and toxic shock syndrome.
Differentiating COVID-19-associated multisystem inflammatory syndrome Disease from other disease
- COVID-19-associated multisystem inflammatory syndrome must be differentiated from other diseases that cause conjunctival injection, cervical lymphadenopathy, and erythematous hands and feet, such as Kawasaki's disease and toxic shock syndrome.[1][2]
| Parameters | COVID-19-associated multisystem inflammatory syndrome (PIMS-TS) | Kawasaki Disease (KD) | Kawasaki Disease Shock (KDS) | Toxic Shock Syndrome (TSS) | Viral Pneumonia[3] |
|---|---|---|---|---|---|
| Age (median, IQR) | 9 (5.7-14) | 2.7 (1.4-4.7) | 3.8 (0.2-18) | 7.38 (2.4-15.4) | < 5 years |
| Total white blood cell count (*10^9/L) | 17 (12-22) | 13.4 (10.5-17.3) | 12.1 (7.9-15.5) | 15.6 (7.5-20) | 10.0 |
| Neutrophil count (*10^9/L) | 13 (10-19) | 7.2 (5.1-9.9) | 5.5 (3.2-10.3) | 16.4 (12-22) | 3.2 (1.0-5.1) |
| Lymphocyte count (*10^9/L) | 0.8 (0.5-1.5) | 2.8 (1.5-4.4) | 1.6 (1-2.5) | 0.63 (0.41, 1.13) | 4.5 (2.7-6.1) |
| Hemoglobin (g/L) | 92 (83-103) | 111.0 (105-119) | 107 (98-115) | 114 (98-130) | - |
| Platelet number (10^9/L) | 151 (104-210) | 365.0 (288-462) | 235 (138-352) | 155 (92- 255) | 387 (+/-174) |
| C-reactive protein (mg/L) | 229 (156-338) | 67.0(40-150) | 193 (83-237) | 201 (122, 317) | 3.4 (0.2-29) |
| ALT (IU/L) | 42 (26-95) | 42.0 (24-112) | 73 (34-107) | 30.00 (22.10, 49.25) | - |
| Albumin (g/L) | 24 (21-27) | 38.0 (35-41) | 30 (27-35) | 27.00 (21.00, 31.00) | - |
| Ferritin (ug/L) | 610 (359-1280) | 200 (143-243) | 301 (228-337) | - | - |
| NT-Pro-BNP (pg/ml) | 788 (174-10548) | 41 (12-102) | 396 (57-1520) | - | - |
| Troponin (ng/L) | 45 (8-294) | 10.0 (10-20) | 10 (10-30) | - | - |
| D-dimer (ng/ml) | 3578 (2085- 8235) | 1650 (970-2660) | 2580 (1460- 2990) | - | - |
- To view the differential diagnosis of COVID-19, click here.
References
- ↑ 1.0 1.1 Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P; et al. (2020). "Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2". JAMA. doi:10.1001/jama.2020.10369. PMC 7281356 Check
|pmc=value (help). PMID 32511692 Check|pmid=value (help). - ↑ Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS; et al. (2020). "Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City". JAMA. doi:10.1001/jama.2020.10374. PMC 7281352 Check
|pmc=value (help). PMID 32511676 Check|pmid=value (help). - ↑ Ruuskanen O, Lahti E, Jennings LC, Murdoch DR (2011). "Viral pneumonia". Lancet. 377 (9773): 1264–75. doi:10.1016/S0140-6736(10)61459-6. PMC 7138033 Check
|pmc=value (help). PMID 21435708.